Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

NCT00001703 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

NIH

Sponsor class

Stopped Due to poor accrual and lack of peptide vaccine

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: incomplete Freund's adjuvant
BIOLOGICAL: von Hippel-Lindau peptide vaccine

Sponsor

National Cancer Institute (NCI)